Winning the Race on Biosimilars
|
|
- Josephine Henderson
- 6 years ago
- Views:
Transcription
1 BioPharma Product Testing Winning the Race on Biosimilars By Dr Jon S Kauffman, Dr Weihong Wang and Dr Frederic Girard at Eurofins European Biopharmaceutical Review ISSUE 76 JULY 2016 UNFOGGING THE FUTURE Personalised medicine has never been closer, thanks to genetic code research COLLABORATE TO CURE Can pooled research unlock the secrets of dementia? BREAKING BARRIERS Understanding the obstacles means faster delivery of RNA therapies to the clinic JULY 2016 Eurofins BioPharma Product Testing pharma@eurofins.com This article is taken from European Biopharmaceutical Review, July 2016, pages Published as 'Winning the Race'. Samedan Ltd
2 Developments in Biosimilars Winning the Race on Biosimilars There are several elements of the biosimilar testing process which, when executed efficiently and with quality levels maintained, allow a successful development programme to be implemented. Is it possible to instigate these methods across the board? Dr Jon S Kauffman, Dr Weihong Wang and Dr Frederic Girard at Eurofins The EMA was the first regulatory body to implement an approval procedure to authorise subsequent versions of previously approved biologics (innovators), termed similar biological medicinal products, or biosimilars. This process is based on a thorough demonstration of comparability of the similar product to an existing approved product (1). The EMA has granted marketing authorisation for 20 biosimilars under this procedure (see Table 1). In the US, the FDA has finalised its long-awaited draft guidance on biosimilars (2,3,4), providing a regulatory framework for the approval of a biologic demonstrated to be similar to an already marketed product. To date, the FDA has approved just one biosimilar Zarxio (filgrastim-sndz). Accelerated Development With patents for many biologic blockbusters expiring soon, estimates of the potential market size for biosimilar drugs continue to be adjusted upward by quantum leaps. These events have resulted in an acceleration of biosimilar development in the EU, Asia and the US. As patents on popular biological medical products begin to expire, drug manufacturers are competing to get their biosimilars to market in a timely, cost-effective manner. Table 2 lists the key targets of biosimilar developers. A vital component to being the first to market is the ability to efficiently navigate the vast analytical testing requirements for the development of biosimilars. Regulators demand extensive testing and characterisation of the biosimilar to show that it is highly similar to the reference product. For biosimilars, the extent of characterisation determines the need for additional nonclinical and clinical studies, thus shifting more analytics to the front of the development process and escalating its importance. Therefore, this evolution in the biopharmaceutical industry involves many players, but none more dramatically than a biopharmaceutical product testing laboratory. Some important strategies for streamlining the required testing discussed here include comprehensive characterisation using mass spectrometric approaches and Table 1: The EMA has granted marketing authorisation for 20 biosimilars Medicine name Abasaglar Abseamed Accofil Bemfola Benepali Binocrit Biograstim Epoetin alfa hexal hexal Grastofil Inflectra Nivestim Omnitrope Ovaleap Ratiograstim Remsima Retacrit Silapo Tevagrastim Zarzio Common name Insulin glargine Epoetin alfa Follitropin alfa Etanercept Epoetin alfa Epoetin alfa Infliximab Somatropin Follitropin alfa Infliximab Epoetin zeta Epoetin zeta 2
3 Table 2: The key targets of biosimilar developers Aranesp (darbepoetin alfa) Avastin (bevacizumab) Enbrel (etanercept) Epogen/Procrit/Eprex/Erypo (epoetin alfa) Erbitux (cetuximab) Herceptin (trastuzumab) Humira (adalimumab) Neulasta (pegfilgrastim) Neupogen (filgrastim) Remicade (infliximab) validated bioassays, efficient development and validation of robust methods, simultaneous installation of methods into multiple testing facilities, and access to extensive capacity for process validation plus stability and release testing. Characterisation Techniques As stated earlier, intensive characterisation is crucial to the success of a biosimilar candidate. Mass spectrometry (MS) coupled with liquid chromatography (LC) is an extremely powerful characterisation tool for these large, complex biomolecules. Contemporary top-down and middle-up approaches using LC-MS and various novel separation techniques can be implemented to measure primary structure, including amino acid sequence, intact masses of the whole protein and associated subunits or domains. Similarly, the current state of classical peptide mapping using LC and tandem mass spectrometry (LC/MS/MS) with scan-dependent acquisition speeds analysis and provides information on post-translational modifications, glycosylation and disulfide mapping in an efficient manner. A full understanding of glycan structure is critical to a wellcharacterised biosimilar. Historically, glycoprofiling is a time-intensive and tedious analytical undertaking. However, novel labelling schemes that are sensitive to both detection by fluorescence and MS can be utilised for thorough and efficient glycoprofiling. Other characteristics of the biosimilar that are typically studied and compared to the innovator include charge and size heterogeneity by electrophoresis, secondary and tertiary structure by circular dichroism, thermal stability by differential scanning calorimetry, aggregation by size exclusion chromatography, and a variety of other techniques. The 2015 FDA Draft Guidance on Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (3) also acknowledged other methods able to further characterise 3D conformation of a protein, which plays an important part in its biological function. Among these, multi-dimensional nuclear magnetic resonance (NMR) spectroscopy can help define tertiary protein structure and, to varying extents, quaternary structure, and can add to the body of information supporting biosimilarity. NMR is a structural tool that is inherently multiplexed. It has a demonstrated ability to rapidly assess protein folding, characterise glycans and determine protein structure. This final application is particularly important as proposed US guidance calls specifically for NMR structural characterisation for biosimilar molecules. It is most Image: Mike at Orbi 3
4 suited for small protein therapeutics, and can as such be used to support biosimilarity demonstration leading to a high level of structural resolution and details. Nevertheless, applying NMR fingerprinting approaches, even on very large biomolecules such as monoclonal antibodies, can also be considered. Indeed, the maps that can be derived and compared between innovator and biosimilar products are, in principle, direct fingerprints of the primary sequence and folding of the protein. In addition to biochemical assays, biological potency testing is another critical aspect of biosimilar product characterisation. A fully developed/validated biopotency assay that speaks to the mechanism of action of the product and uses the innovator product as the reference standard allows direct, head-tohead comparison between the biosimilar products and its innovator version. In general, a cell-based potency assay is preferred by the regulatory agents, since it is considered more physiologically relevant. It is of importance to note that in some cases, post-marketing clinical research has provided clear evidence that additional mechanism of action(s) beyond what was originally focused on during innovator product development is crucial to their clinical efficacy. Correspondingly, the bar on biopotency testing has been raised for the respective biosimilar products to include multiple assays that reflect all known mechanism of action(s) in order to provide a more comprehensive comparability assessment. Method Implementation Methods that exist for innovator products can be difficult to obtain, or can lack sufficient detail for quick method establishment in the laboratory. Therefore, biosimilar programmes tend to be method development-intensive, and it is critical to utilise testing labs that have built up a strong knowledge base around these biopharmaceutical products. Further, many biosimilar developers plan to market and release drug products in various geographic locations (in both the US and EU), and will therefore need analytical testing support in multiple testing facilities. The traditional system is to develop and validate methods in one lab and then perform method transfer to a second. An alternative approach to accelerate method installation at multiple sites is to execute co-validation of methods. Under a well-written protocol, validation activities can be performed at two labs. This allows for methods to be installed simultaneously in both facilities, thus greatly expediting the process and decreasing the cost. When planning for method implementation, potency testing stands out as the most challenging and time-consuming task. Due to the complexity of the assay, the technical expertise of the testing lab in particular is of paramount importance, but many improvements in potency assay approaches have been made during the last five to 10 years. Regulatory scrutiny and general expectations on potency assay testing have also increased dramatically. Therefore, identifying a partner testing lab that has demonstrated experience and regulatory knowledge in the relevant biosimilar product(s) is critical to the successful and timely implementation of potency testing. Choosing a Partner Careful consideration must be given when choosing a testing lab partner as programmes move into stability and release testing, as well as process validation activities. Several key points to consider include capability, capacity and project management. About the authors Dr Jon S Kauffman is Senior Director of Biochemistry, Method Development & Validation, Protocol Development and Technical Writing at Eurofins Lancaster Laboratories. His teams are responsible for developing and validating methods and performing analysis of clinical and commercial samples for stability and release purposes. Jon's key roles are to interface with clients and his team to ensure positive project outcomes by maintaining compliance and a high level of quality. He earned a doctorate in Chemistry from the University of Delaware and has over 25 years experience in the analytical testing field. jonkauffman@eurofinsus.com Dr Weihong Wang is Technology Development Manager for Eurofins Lancaster Laboratories Molecular and Cell Biology group. Serving as a subject matter expert and direct technical contact to assist clients with testing needs, Weihong has 15 years of experience developing and characterising biopharmaceutical products and has extensive experience with enzyme-linked immunosorbent assays and cell-based assays. She has earned a PhD in Cell and Molecular Biology from Brandeis University and completed postdoctoral research at Harvard Medical School. weihongwang@eurofinsus.com Dr Frederic Girard is founder and Managing Director of Eurofins Spinnovation Analytical BV. Spinnovation delivers analytical R&D and QC testing services to support Small Molecules CMC and Biologics Upstream and Downstream Processing activities. Frederic is responsible for the management of operations and is also strongly involved in sales and business development activities. He earned a Master s degree in Chemistry with a minor in Biology, and a PhD in Biophysical Chemistry from the University Orleans in France. Frederic has over 15 years professional experience in the analytical R&D, with many years dedicated to NMR spectroscopy. fredericgirard@eurofinsus.com 4
5 Biosimilar programmes require quite a wide variety of testing and expertise. There is a regulatory expectation that key characteristics linked to critical quality attributes are measured with orthogonal methods, so multiple methods may be used to measure purity or other aspects. Therefore, the testing lab must have the capability to perform a wide array of physiochemical, microbiological and biochemical assays. These activities and assays encompass a broad range of skill sets, expertise, equipment and instrumentation. In conjunction with the capabilities, it is imperative that the testing lab has adequate capacity. Stability and release studies and process validation have the potential to produce many samples that need to be tested in a relatively short timeframe. Therefore, redundancy of specialised equipment and trained staff must be considered. Lastly and just as important as capability and capacity strong project management is paramount. Large biosimilar programmes can be logistically challenging and require a tremendous amount of planning, forecasting, scheduling, follow-up and communication. Regular calls and meetings between the sponsor and testing lab are crucial. A wellrun meeting should be agenda-driven and followed up with minutes and action items in a timely manner. Key discussion topics might include: planning for upcoming pulls or process validation submittals; sample status; outof-specification and anomalous results; investigations; and reference standards management. A proficient project manager must be able to effectively interface with the various testing labs, quality assurance, stability storage, contract manufacturers and the biosimilar sponsor. Therefore, the testing lab should have a proven track record in managing these types of programmes. Ensuring all of these components of testing are performed efficiently, while maintaining a high level of quality, will greatly improve the chances of success of a biosimilar programme. References 1. EMA, Guideline on similar biological medicinal products, CHMP/437/04 Rev 1, FDA, Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product, FDA, Guidance for industry: Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product, FDA, Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009, 2015 The Largest Global Footprint of Harmonized Testing Labs... With the largest network of harmonized bio/pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing is everywhere you are. While delivering a true local lab experience, our international presence ensures personal quality service backed by a unique global breadth of harmonized capabilities to solve all your testing challenges. For the most complete range of global testing services, harmonized quality systems and LIMS, you ll never need to look further than your own backyard. Right In Your Backyard. BioPharma Product Testing Services Facilities Chemistry/Biochemistry Cell Banking Services Facility & Process Validation GMP Manufacturing Method Development & Validation Microbiology Molecular & Cell Biology Raw Materials Testing Release Testing Stability Testing & Storage Viral Clearance & Viral Safety Professional Scientific Services Australia Belgium Denmark France Germany Ireland Italy Netherlands Spain Sweden UK US
6 BioPharma Product Testing Eurofins BioPharma Product Testing 6
Expectation for the future and the role of the JP
JP 130 th Anniversary Symposium (15 September, 2016) Expectation for the future and the role of the JP From Academia s perspectives Toru KAWANISHI, PhD Director-General National Institute of Health Sciences
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationGlobal Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity
Global Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual BioProcess International Europe 2012 Apr 18-19 Prague, Czech Republic BioProcess Technology
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationWhat next? Manufacture the biosimilar product
What next? Manufacture the biosimilar product Design manufacturing process to match QTPP Full quality dossier required. Use state of the art technologies In accordance with relevant ICH and CHMP guidelines
More information: Regulation of biosimilars and success factors for uptake in clinical practice. Steinar Madsen, MD, FACP(Hon) Medical director
2018-02-08: Regulation of biosimilars and success factors for uptake in clinical practice Steinar Madsen, MD, FACP(Hon) Medical director steinar.madsen@legemiddelverket.no Drug costs in Norway Billion
More informationBiosimilar medicines: practical EU experience and perspectives. 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe
Biosimilar medicines: practical EU experience and perspectives 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe Medicines For Europe VISION Medicines for Europe Vision 2020 Our
More informationPharmacovigilance for Biosimilars
Pharmacovigilance for Biosimilars Dr. Niraj Chhaya Risk Management, Global Pharmacovigilance Boehringer Ingelheim GmbH 5th Annual Pharmacovigilance Forum, GLC Europe 03 March 2017 Berlin, Germany Disclaimer
More informationHow are biosimilars assessed and approved?
How are biosimilars assessed and approved? Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific Advice
More informationLAW: Primer on biosimilar agents
AND AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS 2 CPE CREDITS EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM Educational Objectives After participating
More informationClinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View)
Athens, May 25, 2018 Clinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View) Vs18e28 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy &
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Overview of the Regulatory Pathway and FDA s Guidance for the Development and Approval of Biosimilar
More informationRegulatory Consideration for the Characterization of HOS in Biotechnology Products
Regulatory Consideration for the Characterization of HOS in Biotechnology Products Maria Teresa Gutierrez Lugo, Ph.D. OBP/CDER/FDA 5 th International Symposium on Higher Order Structure of Protein Therapeutics
More informationBiosimilars. Their regulatory status and their use
Biosimilars Their regulatory status and their use Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific
More informationRegulation of Biosimilars in Canada
Regulation of Biosimilars in Canada Session 2: Global Regulatory Trends of Biosimilars GBC 2018 June 28, 2018 Stephanie Hardy Office of Policy and International Collaboration Biologics and Genetic Therapies
More informationbiosimilar medicines better access. better health. handbook medicines
biosimilar medicines better access. better health. biosimilar medicines handbook 3 rd edition - 2016 biosimilar medicines better access. better health. biosimilar medicines handbook ABOUT THE BIOSIMILAR
More informationThe Changing Landscape of Mammalian Cell Culture Manufacturing Capacity
The Changing Landscape of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual bioprocessuk Conference Nov 30-Dec 1 2011 Glasgow, Scotland BioProcess Technology Consultants
More informationNaming, tracing, switching and other safety issues after 10 years learning
Naming, tracing, switching and other safety issues after 10 years learning Prof. Dr. Irene Krämer, Department of Pharmacy Johannes Gutenberg-University Medical Center, Mainz (Germany) Disclosures Speaker
More informationReference Standards to Support the Development of Biosimilars
Reference Standards to Support the Development of Biosimilars Jane Robinson & Adrian Bristow Jane.Robinson @nibsc.org Adrian.Bristow@nibsc.org The National Institute for Biological Standards and Control,
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationBiosimilar Product Structural Characterization - Strategies for Comparability Analysis.
Biosimilar Product Structural Characterization - Strategies for Comparability Analysis. Dr Fiona M Greer Global Director, BioPharma Services Development, SGS M-Scan CASSS 8th Symposium on the Practical
More informationThe Regulatory and Licensing Process. Dr Anne Cook, Biologicals Quality Assessor, MHRA
The Regulatory and Licensing Process Dr Anne Cook, Biologicals Quality Assessor, MHRA Outline of presentation Licensing Division at MHRA Development/licensing of originator biological medicines Basis of
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationBiosimilars Market Update
Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto
More informationAn Update on Biosimilars and Biosimilar Litigation in the US
An Update on Biosimilars and Biosimilar Litigation in the US Paul A. Calvo, Ph.D. 1 February 2016 2 nd Biologics and Biosimilars Congress - Berlin Years of Nothing and Now 2 Biosimilar approvals in Europe*
More informationBiosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective)
Soul, September 14, 2017 Biosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective) Vs17i13 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationAssistant Professor Mohammad A Alsenaidy, MSc, PhD, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Assistant
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationTechnical Challenges in the Development of Biosimilars. E. Morrey Atkinson, PhD Interphex May 1, 2012
Technical Challenges in the Development of Biosimilars E. Morrey Atkinson, PhD Interphex May 1, 2012 FDA Guidance on Biosimilarity Guidance for Industry: Scientific Consideration in Demonstrating Biosimilarity
More informationAn update on development strategies of recently approved biosimilars in Europe. Johanna Mielke
An update on development strategies of recently approved biosimilars in Europe Johanna Mielke Acknowledgement & disclaimer This project was supported by the Swiss State Secretariat for Education, Research
More informationBIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS
BIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS George Dranitsaris B.Pharm. PhD Consultant in Health Economics and Biostatistics What is a Biosimilar? Protein based drugs are made
More informationAnalytical similarity: Lessons from the first US biosimilar
Analytical similarity: Lessons from the first US biosimilar 2nd FDA/PQRI Conference on Advancing Product Quality Oct. 5-7, 2015 Corinna Sonderegger, Head Pharmaceutical Development Sandoz Biopharmaceuticals,
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationvfa/vfa bio Position Paper Biopharmaceuticals Original Products and Biosimilars
vfa/vfa bio Position Paper Biopharmaceuticals Original Products and Biosimilars vfa/vfa bio Position Paper Biopharmaceuticals Original Products and Biosimilars EXECUTIVE SUMMARY vfa and vfa bio represent
More informationThe new innovations of mab biolimilars and antibody therapeutics Our dedication to human health
Prestige The new innovations of mab biolimilars and antibody therapeutics Our dedication to human health New Biosimilar Development A Frontier in Biopharmaceuticals Antibody Therapeutics Development Prestige
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationUpdate on Biosimilars
Update on Biosimilars From Fiction to Formulary Natalie Nguyen, Pharm.D. PGY1 Pharmacy Administration Resident Virginia Commonwealth University Health System Disclosures I have no disclosures or conflicts
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationWhat Is a Biosimilar?
Learning Objectives Compare and contrast biosimilars to their reference product and generic therapies in terms of structure, manufacturing, regulatory pathway, and clinical properties Evaluate evolving
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationWhat is a biosimilar and how does sound biosimilar use look like?
Vs14f17 LBP Opleidingsinstituut voor Care & Cure: Biosimilars in the Market; what does it mean for us? Rotterdam, June 18, 2014. What is a biosimilar and how does sound biosimilar use look like? Arnold
More informationRequirements for demonstrating biosimilarity of monoclonal antibodies
Requirements for demonstrating biosimilarity of monoclonal antibodies Dr. Steffen Gross Section Mono-/Polyclonal Antibodies Paul-Ehrlich-Institut Germany http://www.pei.de Outline Biosimilars Regulatory
More informationPharmaceutical market
3/14/218 Pharmaceutical market Hynek Valerián Copyright 218 IQVIA. All rights reserved. Table of Contents + Global pharmaceutical market Regions and growth contribution Biologic products + Czech Republic
More informationGlobal Biosimilar Market Trends & Opportunities: 2015 Edition
Global Biosimilar Market Trends & Opportunities: 2015 Edition Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected
More informationThe future of biosimilars
5 The future of biosimilars monoclonal antibodies and beyond Author Ash Ramzan, Principal Consultant, Woodley BioReg Ltd, UK. Keywords Biopharmaceutical; Biosimilars; Monoclonal antibody (mab); Switching/interchangeability;
More informationInternational Evolution
EMA Biosimilar update: International Regulatory Convergence Presented by: Peter Richardson, 29 April 2016 Head of Quality Office Specialised Scientific Disciplines Department, EMA An agency of the European
More informationPh. Eur. monographs and biosimilars
Ph. Eur. monographs and biosimilars Emmanuelle Charton, Ph. D. European Pharmacopoeia Department European Directorate for the Quality of Medicines & HealthCare 1 Place of the Ph. Eur. within the EU regulatory
More informationHow much evidence is provided prior to approval? An updated systematic review of biosimilar applications in Europe
How much evidence is provided prior to approval? An updated systematic review of biosimilar applications in Europe Johanna Mielke (johanna.mielke@novartis.com), Byron Jones, Franz Koenig, Bernd Jilma This
More informationComparability to establish Biosimilarity
Comparability to establish Biosimilarity CMC Strategy Forum Europe 2014, Sorrento, Italy Jan Visser, Head Global Analytical Characterization & Bioanalytics Sandoz Biopharmaceuticals, Hexal AG, Germany
More informationBiotherapeutic product characterization to support accelerated process development
Biotherapeutic product characterization to support accelerated process development Kyle Zingaro, Ph.D. Alexion Pharmaceuticals 2015 Biomanufacturing Technology Summit June 25, 2015 Our Mission: Treating
More informationCell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products
Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products Founded in 96, Eurofins Lancaster Laboratories is a global leader in comprehensive laboratory services enabling
More informationBIOSIMILARS view from Slovak Medicine Regulatory Agency on topic
BIOSIMILARS view from Slovak Medicine Regulatory Agency on topic SARAP SUKL: Regulatory conference, Bratislava, Slovakia, June, 3, 2013 PharmDr. Jan Mazag Director of State Institute for Drug Control,
More informationBIOSIMILAR PROFILING SUMMER 2018 ANDREA DETLEFSEN
BIOSIMILAR PROFILING SUMMER 2018 ANDREA DETLEFSEN PROTEIN DRUGS Therapeutic proteins are one of the fastest growing categories of pharmaceuticals Ex: mabs, recombinant proteins As patents expire, biosimilars
More informationPrecision. Proficiency. Proximity.
Precision. Proficiency. Proximity. Precision Accuracy in testing is paramount to ensuring product safety and efficacy. And fast turnaround times are critical to keeping your project on schedule. With
More informationFormulary Considerations for Biosimilars in healthcare systems
Formulary Considerations for Biosimilars in healthcare systems Ahmed Aljedai, Pharm.D., M.B.A, BCPS, FCCP, FAST Assistant Deputy Minister for Therapeutic Affair, MOH,KSA Disclosure Information Formulary
More informationInternational Journal of Research in Pharmacy and Science
Review Article Available online www.ijrpsonline.com ISSN: 2249 3522 International Journal of Research in Pharmacy and Science The Opportunities and Challenges Involved in Registration of Similar Biotherapeutic
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationBiosimilars: The Impact on Academic Pharmacy
Biosimilars: The Impact on Academic Pharmacy George E. MacKinnon III, PhD, MS, RPh, FASHP Founding Dean and Professor College of Pharmacy Vice Provost for Health Sciences Roosevelt University Learning
More informationBiosimilars today and tomorrow
Biosimilars today and tomorrow Dr. Jörg Windisch, Head Global Technical Development PMCA Impuls Vienna, April 23, 2012 a Novartis company Patient access is at risk because biosimilars are expensive...
More informationBiosimilar regulation from a clinical point of view
Biosimilar regulation from a clinical point of view an update on immunogenicity and interchangeability LIS-TNFBio seminar 2018 Scandic Nidelven Hotel Trondheim 20.-21. mars Senior Advisor Project leader
More informationEUROPEAN GENERIC MEDICINES ASSOCIATION
biosimilars biosimilars contents Introduction... 6 What this Handbook Covers Whom this Handbook is for Executive Summary... 8 The Importance of Biosimilar Medicines... 11 For Patients For Clinicians For
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationQuality, Safety and Efficacy of Follow-on Biologics Teruhide YAMAGUCHI
Quality, Safety and Efficacy of Follow-on Biologics Teruhide YAMAGUCHI Division of Biological Chemistry and Biologicals National Institute of Health Sciences Quality, Safety and Efficacy of Follow-on Biologics
More informationCOPYRIGHTED MATERIAL QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS. Rohin Mhatre and Anurag S. Rathore 1.1 INTRODUCTION
1 1.1 INTRODUCTION QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS Rohin Mhatre and Anurag S. Rathore The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should
More informationWhat do physicians expect from a new drug?
What do physicians expect from a new drug? New drug Novel activity Efficacy Safety Affordable cost Approval of new biologic drugs Is consistently increasing New Biotech Drug and Vaccine Approvals/ New
More informationAnalytical Characterization of Biotherapeutics: Looking to the Future with Biosimilars
Analytical Characterization of Biotherapeutics: Looking to the Future with Biosimilars Jared Auclair, Ph.D. Northeastern University Department of Chemistry and Chemical Biology Barnett Institute of Chemical
More informationMedicines Agency EMA & Biosimilar update: Trends from marketing authorisation applications, scientific advice procedures and policies
EMA & Biosimilar update: Trends from marketing authorisation applications, scientific advice procedures and policies Presented by: Peter Richardson Head of Quality Office Specialised Scientific Disciplines
More informationas they ordinarily would for a generic. This has been a key factor inhibiting biosimilar uptake.
PEB OVR 6.1 Agenda Item 6 BIOSIMILARS REIMBURSEMENT 1 Purpose of Item 1.1 The Minister (delegate) requests the Pharmaceutical Benefits Advisory Committee (PBAC) provide advice on the following matter(s)
More informationBiosimilars today or tomorrow?
Oxford Inflammatory Bowel Disease MasterClass Biosimilars today or tomorrow? Dr Vipul Jairath Bsc DPhil MRCP NIHR Clinical Lecturer Translational Gastroenterology Unit University of Oxford John Radcliffe
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Killarney, 22-24 May 2017 An agency of the European Union Overview International collaboration
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationRegulatory Updates for Biopharmaceutical Products:FDA Perspective
Regulatory Updates for Biopharmaceutical Products:FDA Perspective CMC Strategy Forum Europe 2016 Sarah Kennett Division of Biotechnology Review and Research I Office of Biotechnology Products OPQ,CDER,
More information3D Structure of Biologics in a Convenient Immunoassay Format
3D Structure of Biologics in a Convenient Immunoassay Format Xing Wang, Ph.D. Array Bridge Inc. 5/25/2017 1 Topics Covered Today Why New Technologies? Technology Development. Case Studies for Novel and
More informationFDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA
FDA recommendations for comparability studies to support manufacturing changes Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA The views and opinions expressed here should not be used
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationThe United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts
The United States Pharmacopeia Strategy on Biotherapeutic Products Standards Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts U.S. Pharmacopeia Who We Are Scientific, independent, volunteer-driven,
More informationPractical challenges in the CMC development of biosimilars. Simon Hotchin Executive Director Regulatory Affairs Amgen Inc.
Practical challenges in the CMC development of biosimilars Simon Hotchin Executive Director Regulatory Affairs Amgen Inc. Overview Introduction Statistical methodologies in the assessment of analytical
More informationOvercoming the gap between clinical use of biosimilars and education of pharmacists and other healthcare providers
Glasgow, September 1, 2018 Overcoming the gap between clinical use of biosimilars and education of pharmacists and other healthcare providers Vs18h01agv Liese Barbier PharmD Arnold G. Vulto PharmD PhD
More informationBiosimilars, Regulatory Framework and Outcome So Far
1 Biosimilars, Regulatory Framework and Outcome So Far Inger Mollerup Vice President Regulatory Affairs, Novo Nordisk Sep 24/09/2009 28 2009 1 Disclaimer The views and opinions expressed in the following
More informationHOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT
HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT INTRODUCTION Biopharmaceuticals require products to be free of residual host cell protein (HCP) contaminants from the bioprocessing workflow. To evaluate
More informationJefferies 2016 Healthcare Conference. June 8, 2016
Jefferies 2016 Healthcare Conference June 8, 2016 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
More informationPatiënten-onderzoeken naar overstappen Wat leren we van trials en registries
3rd Dutch National Biosimilar Symposium 12 April 2018, Rotterdam Patiënten-onderzoeken naar overstappen Wat leren we van trials en registries Liese Barbier PhD researcher KU Leuven MABEL Fund Disclosure
More informationImmunogenicity: Impact on the Design of Clinical Trials for Biosimilars
Immunogenicity: Impact on the Design of Clinical Trials for Biosimilars Alexander Berghout, M.D., Ph.D. Head Global Clinical Research and Development Sandoz Biopharmaceuticals BMWP/BWP Workshop on Immunogenicity
More informationConsiderations on WHO s BQ Proposal
Considerations on WHO s BQ Proposal Joerg Windisch, PhD, Chair European Biosimilars Group (EBG) Chief Science Officer, Sandoz Biopharmaceuticals 60 th INN Consultation WHO, Geneva, April 13 th, 2015 Thank
More informationIMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY
IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY Research, development and production of biopharmaceuticals is growing rapidly, thanks to the increase of novel therapeutics and biosimilar
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationCell Processing Workstation. In Situ Laser-Mediated Cell Purification and Processing
LEAP Cell Processing Workstation Cell Processing Workstation In Situ Laser-Mediated Cell Purification and Processing Expanding the Capabilities of Cell Processing Consistent, High-Yield, High-Purity Processing
More informationWhat is the Role of HTA for Biosimilars? Jorge Mestre-Ferrandiz and Adrian Towse, Office of Health Economics
April 2014 Briefing 54 What is the Role of HTA for Biosimilars? Jorge Mestre-Ferrandiz and Adrian Towse, Office of Health Economics This Briefing contains a summary of the main points and conclusions from
More informationPRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference**
PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference** The Future of Biologics Development and Manufacturing 20 April 2017 13:00 16:00 Big Sight Exhibition Center,
More informationThe. Altascientist SEPTEMBER 2018 ISSUE NO. 4
The Altascientist SEPTEMBER 2018 ISSUE NO. 4 Altasciences has the perfect mix of innovator and generic drug development experience, with a thorough understanding of the regulatory complexities involved
More informationThere are no secrets to success. It is the result of preparation, hard work, and learning from failure. Colin Powell
Welcome 1 2 There are no secrets to success. It is the result of preparation, hard work, and learning from failure. Colin Powell 5 FACTS about us 3 Established offers clinical Manufacturing sites Compliant
More informationQuality attributes impacting immunogenicity of therapeutic proteins
www.pei.de Quality attributes impacting immunogenicity of therapeutic proteins Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins 9th March 2016 (EMA, Room 3A) Steffen
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationAre Biosimilars the Panacea for High Cost Specialty Drugs?
Are Biosimilars the Panacea for High Cost Specialty Drugs? Mid-sized Retirement and Healthcare Plan Management San Francisco, CA March 27, 2018 2018. Innovative Rx Strategies, LLC. All rights reserved.
More informationMass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations
Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER Food and Drug Administration
More information